MacroGenics Presents MGC026 Data Showing 27.3% Best Overall Response Rate in Head and Neck Cancer

• MacroGenics presented MGC026 data at ESMO showing a 27.3% best overall response rate in 22 heavily pretreated head-and-neck cancer patients.
• Confirmed responses reached 18.2%; the disease control rate was 63.6%.
• No treatment-related discontinuations occurred in the 27-patient expansion cohort; no interstitial lung disease, pneumonitis or ocular toxicity was reported.
• A front-line MGC026-pembrolizumab combination study is planned for early 2027, with the next MGC026 update anticipated mid-2027.
• Pro forma cash equivalents and marketable securities totaled $327 million, supporting a projected cash runway through 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MacroGenics Inc. published the original content used to generate this news brief on October 24, 2026, and is solely responsible for the information contained therein.